Skip to main content

Advertisement

Table 2 Adverse Events (Grade 1 + 2; ≥ 2%)

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Adverse Event Number Percent
Nausea 23 38
Fatigue 13 21
Emesis 10 16
Rash 9 15
Chills 6 10
Back Pain 5 8
Weight Loss 4 7
Weakness 4 7
Pruritis 4 7
Poor Appetite 4 7
Shortness of Breath 4 7
Pain At Tumor Site 3 5
Insomnia 3 5
Lethargy 3 5
Rib Pain 2 3
Fever 3 5
Ascites 2 3
Cellulitis 2 3
Diarrhea 2 3
Pedal Edema 2 3
Hypotension 1 2
Cough 1 2
Whole Body Rash 1 2
Neck Pain 1 2
Presyncope 1 2
Malaise 1 2
Fluid Retention 1 2
Poor Oral Intake 1 2
Head Sweats 1 2
Diffuse Body Aches 1 2
Erythema 1 2
Abdominal Pain 1 2
Gait Imbalance 1 2
Pleuritis 1 2
Jaundice 1 2
Constipation 1 2
Nipple Irritation 1 2
Xerostomia 1 2
Chest Thrombosis 1 2
Vitiligo 1 2
Visual Disturbance 1 2
Diplopia 1 2
Perioral Numbness 1 2
Pruritus in Eyes 1 2